Health

ForumHealth

Pharma + payer + provider + medtech + health-IT — one synthesis layer.

Five sub-modules covering the value chain end to end: pharma/biotech (development → approval → launch), payer (CMS + commercial), provider (systems + IDNs), medtech, health-IT.

Start free on ForumHealth See a sample brief

Source landscape

813+

catalogued health sources — regulatory, financial, trade press, academic, patents, court records, vendor blogs, conference catalogs

PhasePhase 1 — active build

Sub-modules5

Personas tuned6

Wave-2 target300+ sources

Featured entities

Pfizer UnitedHealth HCA Healthcare Moderna Epic Systems

Personas

Six tuned briefs for the health buyer set.

Each persona gets section structure, source weights, and citation depth tuned to its job-to-be-done. Briefs are 400–800 words and arrive at 06:00 customer local.

Pharma-biotech equity analyst

Healthcare VC + growth

Payer + provider strategy + M&A

Health regulatory counsel (FDA + CMS + DOJ + FTC + state)

Health journalist + analyst

Health-tech founder + commercial operator

Forum Brief — Health

Continuous per-persona daily synthesis across 5 sub-modules. Citation-validated. Voice-readable.

Forum Forecast — Health

Monte-Carlo probability distributions on M&A, regulatory, capacity, and exec movement events. 3 forecast types per persona at v1.

Forum Network — Health

Cross-sector entity graph linking Health entities to their appearances in adjacent sectors. Featuring Pfizer and UnitedHealth.

Brief preview

A recent Health brief — first two sections.

Headlines

Wiz disclosed a $32B all-stock acquisition by Alphabet, clearing antitrust review faster than the Mandiant deal 1 2. Palo Alto Networks raised FY26 product revenue guidance by 300bps on platform-consolidation momentum 3. CrowdStrike's earnings call previewed an ITDR module landing in Q3, narrowing the gap to Microsoft Defender's identity surface 4 5.

Competitor moves

Microsoft positioned its E5+Defender bundle as the default SOC for mid-market customers in a 2026-05-19 Build keynote 6, with Sentinel-as-XDR pricing moving from per-event to per-asset 7. The shift compresses the per-seat economics of pure-play SIEM vendors and directly pressures Splunk's renewal cycle 8.

Zscaler announced a private CrowdStrike-aligned XDR integration in a 2026-05-21 press release 9, telegraphed at RSA 2026 panel discussion 10. Cloudflare's API-security pricing pivoted to consumption-based on 2026-05-23, ending the flat-rate model and aligning with Wiz pricing posture 11.

Competitive teardown

What we add vs. the incumbents.

Each incumbent covers part of the health landscape at a premium price point. Forum Atlas aggregates them — and adds capabilities the human-analyst cost structure cannot fund.

IQVIA

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Evaluate Pharma

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Komodo Health

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Trilliant Health

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Fierce Pharma

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Cross-sector moat

Health entities that touch other sectors.

Forum Network resolves each Health entity across every sector it touches — letting you see, for example, how an M&A move in Tech reshapes Cyber exposure or Defense supplier dynamics.

Microsoft

MSFT

TechCyberSpaceDefenseHealthEnergyFinance

appears in 7 sectors · importance 99.6

Alphabet

GOOGL

TechCyberHealthAutoComms

appears in 5 sectors · importance 98.7

Apple

AAPL

TechCommsHealthAuto

appears in 4 sectors · importance 98.4

Amazon

AMZN

TechInfraHealthCommsEnergy

appears in 5 sectors · importance 98.2

Anthropic

TechCyberHealthFinance

appears in 4 sectors · importance 96.1

NVIDIA

NVDA

TechAutoHealthDefense

appears in 4 sectors · importance 99.1

ForumHealth

Try Forum Atlas on Health.

The free tier includes the top-3 daily items in Health. No credit card.

Start free See pricing

Forum Atlas

Health

ForumHealth

Pharma + payer + provider + medtech + health-IT — one synthesis layer.

Five sub-modules covering the value chain end to end: pharma/biotech (development → approval → launch), payer (CMS + commercial), provider (systems + IDNs), medtech, health-IT.

Start free on ForumHealth See a sample brief

Source landscape

813+

catalogued health sources — regulatory, financial, trade press, academic, patents, court records, vendor blogs, conference catalogs

PhasePhase 1 — active build

Sub-modules5

Personas tuned6

Wave-2 target300+ sources

Featured entities

Pfizer UnitedHealth HCA Healthcare Moderna Epic Systems

Personas

Six tuned briefs for the health buyer set.

Each persona gets section structure, source weights, and citation depth tuned to its job-to-be-done. Briefs are 400–800 words and arrive at 06:00 customer local.

Pharma-biotech equity analyst

Healthcare VC + growth

Payer + provider strategy + M&A

Health regulatory counsel (FDA + CMS + DOJ + FTC + state)

Health journalist + analyst

Health-tech founder + commercial operator

Forum Brief — Health

Continuous per-persona daily synthesis across 5 sub-modules. Citation-validated. Voice-readable.

Forum Forecast — Health

Monte-Carlo probability distributions on M&A, regulatory, capacity, and exec movement events. 3 forecast types per persona at v1.

Forum Network — Health

Cross-sector entity graph linking Health entities to their appearances in adjacent sectors. Featuring Pfizer and UnitedHealth.

Brief preview

A recent Health brief — first two sections.

View full brief

Headlines

The FDA approved Vera Therapeutics' Trutakna, the first therapy in a new drug class designed to block two targets in immunoglobulin A nephropathy, an autoimmune kidney disease that can progress to end-stage renal failure 1. The approval sets up near-term competitive dynamics in the IgAN space: Vertex Pharmaceuticals is on track for a November regulatory decision on a drug aimed at the same two protein targets 1. On pricing, Vera will charge $425,000 annually for Trutakna before customary insurance discounts and rebates, a figure payers and PBMs will weigh against the competing Vertex asset once it reaches market 2.

Separately, in oncology access, U.K. officials are nearing a pricing deal with AstraZeneca and Daiichi Sankyo intended to secure NHS access to Enhertu, an antibody-drug conjugate shown to extend survival by roughly six months for some breast cancer patients — a reversal after the U.K.'s pricing regulator had previously deemed the medicine not cost-effective 2.

A real Health brief from the live corpus — every claim citation-validated, the same discipline every Forum Atlas brief carries.

Brief preview

A recent Health brief — first two sections.

Headlines

Competitor moves

Competitive teardown

What we add vs. the incumbents.

Each incumbent covers part of the health landscape at a premium price point. Forum Atlas aggregates them — and adds capabilities the human-analyst cost structure cannot fund.

IQVIA

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Evaluate Pharma

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Komodo Health

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Trilliant Health

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Fierce Pharma

Covered + cited in every Health brief where relevant; cross-referenced to the Forum Atlas synthesis layer.

Cross-sector moat

Health entities that touch other sectors.

Forum Network resolves each Health entity across every sector it touches — letting you see, for example, how an M&A move in Tech reshapes Cyber exposure or Defense supplier dynamics.

Microsoft

MSFT